New agents for the treatment of lymphoma

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Stathis, A ^a   Ghielmini, M ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Immunotoxins; Lymphomas; Monoclonal antibodies; Small molecules

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BLINATUMOMAB; BORTEZOMIB; BRENTUXIMAB VEDOTIN; ENZASTAURIN; EVEROLIMUS; FLUDARABINE; FOSTAMATINIB; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; INOTUZUMAB OZOGAMICIN; LENALIDOMIDE; NAVITOCLAX; OBINUTUZUMAB; OCARATUZUMAB; OFATUMUMAB; PACRITINIB; PERIFOSINE; PRO 131921; PROTEIN KINASE B; RITUXIMAB; SAR 3419; TEMSIROLIMUS; TOSITUMOMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD TOXICITY; BLURRED VISION; CANCER RECURRENCE; CANCER RESISTANCE; CEREBELLUM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CONFUSION; CONTINUOUS INFUSION; CORNEA DISEASE; CYTOPENIA; DIARRHEA; DISORIENTATION; DOSE RESPONSE; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL DISEASE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LIVER DYSFUNCTION; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LYMPHADENOPATHY; LYMPHOMA; MACROGLOBULINEMIA; MANTLE CELL LYMPHOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BINDING; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOTHERAPY; IMMUNOTOXINS; LYMPHOMA, NON-HODGKIN; MOLECULAR TARGETED THERAPY; PROTEASOME INHIBITORS; PYRAZINES;

EID: 84866744330     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds310     Document Type: Article

References (37)

1. Mahadevan D, Fisher RI. Novel therapeutics for aggressive non-Hodgkin's lymphoma. J Clin Oncol 2011; 29(14): 1876-1884. Review.
2. Younes A. Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nat Rev Clin Oncol 2011; 8(2): 85-96.
3. Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol 2010; 11(11): 1074-1085. Review.
4. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008; 359(6): 613-626.
5. Beers SA, Chan CH, French RR et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010; 47(2): 107-114.
6. Cragg MS. CD20 antibodies: doing the time warp. Blood 2011; 118(2): 219-220.
7. Teeling JL, Mackus WJ, Wiegman LJ et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177(1): 362-371.
8. Wierda WG, Kipps TJ, Mayer J et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010; 28(10): 1749-1755.
9. Niederfellner G, Lammens A, Mundigl O et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood 2011; 118(2): 358-367.
10. Salles G, Morschhauser F, Thieblemont C et al. Efficacy and safety of obinutuzumab (GA101) monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma: results from a phase I/II study (BO20999). Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 268.
11. Morschhauser F, Cartron G, Thieblemont C et al. Encouraging activity of obinutuzumab (GA101) monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma: results from a phase II study (BO20999). Blood (ASH Annual Meeting Abstracts) 2011; 118: Abstract 3655.
12. Goebeler M, Viardot A, Noppeney R et al. Blinatumomab (CD3/CD19 BITE antibody) results in a high response rate in patients with relapsed non-Hodgkin lymphoma (NHL) including MCL and DLBCL. Ann Oncol (ICML) 2011; 22: Abstract 068.
13. Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res 2011; 17(20): 6417-6427.
14. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28(12): 2085-2093.
15. Goy A, Leach J, Ehmann WC et al. Inotuzumab ozogamicin (INO, CMC-544) in pts with indolent B-cell NHL refractory to rituximab (R), R plus chemotherapy, or radioimmunotherapy (RIT). Ann Oncol (ICML) 2011; 22: Abstract 069.
16. Blanc V, Bousseau A, Caron A et al. SAR3419: SAR3419: an anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 2011; 17(20): 6448-6458.
17. Younes A, Gordon L, Kim S et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2009; 114: Abstract 585.
18. Katz J, Janik JE, Younes A. Brentuximab vedotin (SGN35). Clin Cancer Res 2011; 17(20): 6428-6436.
19. Younes A, Gopal AK, Smith SE et al. Durable complete remissions in a pivotal phase II study of SGN-35 (Brentuximab Vedotin) in patients with relapsed or refractory Hodgkin lymphoma (HL). Ann Oncol (ICML) 2011; 22: Abstract 160.
20. Shustov AR, Advani R, Brice P et al. Complete remissions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2010; 116: Abstract 961.
21. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28(6): 1075-1083.
22. Altman JK, Platanias LC. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008; 15(2): 88-94.
23. Hess G, Herbrecht R, Romaguera J et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829.
24. Smith SM, van Besien K, Karrison T et al. Temsirolimus has activity in nonmantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28(31): 4740-4746.
25. Johnston PB, Inwards DJ, Colgan JP et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85(5): 320-324.
26. Witzig TE, Reeder CB, LaPlant BR et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011; 25(2): 341-347.
27. Kahl B, Byrd J, Flinn I et al. Significant clinical activity of CAL-101, an isoform selective inhibitor of phosphatidylinositol 3 kinase P110D, in patients with relapsed or refractory indolent and mantle cell lymphoma. Ann Oncol (ICML) 2011; 22: Abstract 350.
28. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
29. Mann BS, Johnson JR, Cohen MH et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 2007; 12(10): 1247-1252.
30. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28(29): 4485-4491.
31. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19(5): 964-969.
32. Sureda A, Engert A, Browett PJ et al. Interim results for the phase II study of panobinostat (LBH589) in patients (Pts) with relapsed/refractory Hodgkin's lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). J Clin Oncol (ASCO Meeting Abstracts) 2010; 28: 8007.
33. Younes A, Oki Y, Bociek RG et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12(13): 1222-1228.
34. Fisher RI, Bernstein SH, Kahl BS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24(30): 4867-4874.
35. Ruan J, Martin P, Furman RR et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29(6): 690-697.
36. Fowler N, Hagemeister F, Mclaughlin P et al. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-hodgkins lymphoma. Ann Oncol (ICML) 2011; 22: Abstract 137.
37. Nowakowski G, Reeder CB, Laplant B et al. Combination of lenalidomide with R-CHOP (R2CHOP) is safe and effective as initial therapy for aggressive B-cell lymphomas-a phase I/II study. Ann Oncol (ICML) 2011; 22: Abstract 110.